Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L. Berry, Francis L. Munier, Brenda L. Gallie, Ashley Polski, Sona Shah, Carol L. Shields, Dan S. Gombos, Kathleen Ruchalski, Christina Stathopoulos, Rachana Shah, Rima Jubran, Jonathan W. Kim, Prithvi Mruthyunjaya, Brian P. Marr, Matthew W. Wilson, Rachel C. Brennan, Guillermo L. Chantada, Murali M. Chintagumpala, A. Linn Murphree

Research output: Contribution to journalArticle

Abstract

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression-free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

Original languageEnglish (US)
Article numbere28964
JournalPediatric Blood and Cancer
Volume68
Issue number5
DOIs
StateAccepted/In press - 2021

Keywords

  • clinical trials
  • imaging
  • ocular oncology
  • response criteria
  • retinoblastoma
  • ultrasonography

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Response criteria for intraocular retinoblastoma: RB-RECIST'. Together they form a unique fingerprint.

Cite this